19-Nov-2026 11:14:24
BETA : SIGNS ALGERIA ONCOLOGY JV FOR $8.7 MN
• Board approved JVA with IMGSA Groupe SPA to incorporate JV company IMGSA Oncologie SPA in Algeria for manufacturing and marketing oncology formulations • Beta to hold 49% and IMGSA 51%, as Algeria limits non-resident ownership to 49% in pharma; Beta to run day-to-day operations • Total investment in JV USD 8.7 million; Beta's investment USD 3 million over 3 years plus technology transfer valued at USD 1.26 million • JV to take over IMGSA's oncology plant for total consideration USD 8.7 million; plant has injectables and oral solid dosage lines and supplies Algeria national tenders • Beta gets 3 of 5 board seats, right to appoint CEO/General Manager and affirmative voting on reserved matters • IMGSA recorded turnover of US$100 million for year ended December 2025 with 30% from exports; Beta has supplied formulations to IMGSA for 4 years
Beta Drugs Limited
Open attachment